Board of Directors

Peter Sorger, PhD

Head of the Program in Therapeutic Science,
Harvard Medical School

Otto Krayer Professor of Systems Pharmacology,

Vihann Kong

Constellation an Exelon Company

Manager, Demand Response New England

Andrew Sutherland, MSc

Andrew brings over 18 years of experience in growing and developing financial and operational processes to Applied BioMath. As one of the co-founders, Andrew is responsible for all business matters at Applied BioMath. He has a long track record of successfully driving shareholder value and most recently was head of finance and administration at Litle & Co., which was acquired by Vantiv in 2012. Prior to Litle, Andrew worked for a number of startups, all in finance and administration roles.

Joshua Apgar, PhD

Before co-founding Applied BioMath, Josh was a Principal Scientist in the Systems Biology Group of the Department of Immunology and Inflammation at Boehringer Ingelheim Pharmaceuticals. His work leveraged physics-based models to: translate in vitro and in vivo data, assess target feasibility, understand drug mechanism of action, and predict human doses. The ultimate goal of this work was to reduce late stage attrition in drug development through a deep and quantitative interrogation of drug pharmacology and disease pathophysiology.

John M. Burke, PhD

Dr. Burke’s BS and MS are in Applied Mathematics from the University of Massachusetts, Lowell, in 1993 and 1995, respectively. His PhD degree is in Applied Mathematics from Arizona State University in 2003. His research interests include singularly and randomly perturbed differential equations, bifurcation theory, and applying dynamical systems theory to study and understand how cells and tissues make decisions in humans, and human disease. Prior to co-founding Applied BioMath, Dr. Burke joined Boehringer Ingelheim in 2008 as Associate Director, Head of Systems Biology.